Products & Services, Business & People, Manufacturers & Providers
Medicines for Europe: Generic medicines save European countries 100 billion euro per year
According to a recent press release issued by Medicine for Europe (formerly EGA), this is one of the conclusions of the IMS Institute for Healthcare Informatics study on The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective.
- Insights Issuer:
- European Generic Medicines Association
- Insights ID:
- HARE 4893 2016
- Insights Published by:
- Insights Date:
- Insights Type:
- Media News
- Insights Publishing Date:
Thus, the study concluded that by 2050 the European population aged over 65 will increase from 129 to 191 million, with a consequent increase in the incidence of chronic diseases and the corresponding impact on the health expense of states. Between 2005 and 2014, generic medicines made it possible for European countries to double the number of patients treated, whilst maintaining the same pharmaceutical budget.
The study Value of Generic Medicines – Health Economics Study conducted by IGES Institute for Medicines for Europe also presented, concludes also that with the use of generic medicines, it is possible to treat a considerably a greater number of patients suffering from hypertension maintaining the same levels of expenditure; treat as many patients with breast cancer with lower levels of expenditure and treat more patients suffering from depression, with a slight increase in expense.
The seminar was attended by national and international experts as Adrian van den Hoven, Medicines for Europe Director General, António Vaz Carneiro, Professor, Faculty of Medicine of Lisbon and Director of CEMBE, Carlos Gouveia Pinto, Associate Professor of ISEG, Hélder Mota Filipe, member of the Board of INFARMED, IP or Paul Lilaia, President of APOGEN.
In an unexpected move, just before the end of 2011, ...
Improving expenditure efficiency has been, for a ver...
Your Portal Link to Mass Media Universe.
Valuable Quarterly Romanian Market Analysis.
Ask the analyst
Tailor-made advice for you